Patent Number: 7,612,035

Title: Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma

Abstract: Inhibitors of the MAPK pathway, including MEK-directed proteases and small molecule inhibitors, are cytotoxic to human melanoma cells in vitro and in vivo via apoptotic mechanisms. These compounds are used to kill melanoma cells and to treat subjects with melanoma, either alone or in combination with other therapeutic modalities.

Inventors: Koo; Han-Mo (Kentwood, MI), Koo, legal representative; Eunmi (Kay) (Kentwood, MI), Vande Woude; George F. (Ada, MI), Duesbery; Nicholas S. (Grand Rapids, MI)

Assignee: Van Andel Research Institute

International Classification: A61K 38/00 (20060101)

Expiration Date: 1/03/02017